Former Chairman Receives Final Sentence with 3-Month Reduction from First Trial; Weiying Health: Verdict Has Minimal Impact on Company Financial Results

Everyday Reporter | Zhang Baolian Everyday Editor | Bi Luming

After more than two years of investigation and litigation, the case involving Wei Ning Health (SZ300253, stock price 8.73 yuan, total market value 19.342 billion yuan), a leading company in medical informatization, and its former chairman Zhou Wei has finally been resolved.

On March 22, Wei Ning Health announced that the Intermediate People’s Court of Maoming City, Guangdong Province, issued a final judgment regarding Zhou Wei and the company’s wholly owned subsidiary Shenzhen Wei Ning Zhongtian Software Co., Ltd. (hereinafter “Shenzhen Wei Ning”) for bribery offenses. The court upheld the fine of 800,000 yuan imposed on Shenzhen Wei Ning, and Zhou Wei was sentenced to one year and three months in prison and fined 200,000 yuan.

Although the core founder was involved, the company stated that the outcome of the second-instance judgment has little impact on the company’s profits and losses and will not affect normal business operations. Currently, the company’s management, business operations, and financial condition are normal.

The timeline of this case dates back to July 2023.

On July 1, 2023, Zhou Wei, the actual controller and then-chairman of Wei Ning Health, was placed under detention by the Maoming City Supervisory Committee. On July 5, the company received an official notice of case filing, confirming Zhou Wei was under investigation and detention for suspected bribery. However, Zhou Wei returned to Shanghai from Maoming on August 14, 2023, and resumed normal duties. The case is still under further investigation.

On November 5, 2025, the first-instance verdict was issued. The People’s Court of Dianbai District, Maoming City, Guangdong Province, ruled that: First, Shenzhen Wei Ning committed the crime of bribery by a unit and was fined 800,000 yuan; second, Zhou Wei, as an individual, committed the same crime and was sentenced to one year and six months in prison and fined 200,000 yuan. Both the defendant company and Zhou Wei filed appeals.

On March 22, 2026, Wei Ning Health disclosed that the final second-instance judgment was issued on March 19. The Intermediate People’s Court of Maoming City upheld the first-instance verdict regarding Zhou Wei’s conviction and additional penalties. However, it revoked the primary sentence in the first-instance ruling and sentenced Zhou Wei to one year and three months in prison with a fine of 200,000 yuan.

The judgment states that the sentence duration is from November 5, 2025, to December 21, 2026, with 45 days of pre-trial detention and custody already credited toward the sentence. The announcement noted: “After the second-instance judgment, both the appellant (original defendant company) and the appellant (original defendant individual) have decided to accept the judgment.”

It is noteworthy that Zhou Wei resigned as chairman of the company in November 2025. He no longer serves as a director, supervisor, or senior executive, and now only acts as a consultant, not participating in daily operations. The company has completed governance restructuring through electing a new chairman and changing legal representatives to ensure business continuity.

From an industry perspective, Wei Ning Health operates in the rapidly developing medical informatization sector, with increasing regulatory requirements for compliance. After the final judgment, the market’s main concern is the actual impact on the company’s operations. According to Wei Ning Health’s announcement, the affected subsidiary’s business scale has limited overall impact on the company.

Data shows that Shenzhen Wei Ning is a regional wholly owned subsidiary, operating only in parts of Guangdong. From 2022 to 2024, its revenue was 23.6753 million, 15.6434 million, and 13.652 million yuan, respectively, accounting for less than 1% of Wei Ning Health’s total revenue in the same period; net profits were 9.9939 million, 11.2692 million, and 7.0014 million yuan, respectively, accounting for less than 10% of the company’s net profit in the same period.

The company pointed out that “if Shenzhen Wei Ning’s future operations are restricted due to the above judgment, it is not expected to significantly adversely affect the company’s operations.”

Meanwhile, the fine of 800,000 yuan accounts for 0.9% of the most recent audited net profit attributable to the parent company’s shareholders, and is “not expected to have a significant impact on the company’s current profits.”

However, Wei Ning Health is currently facing macroeconomic challenges, with its performance showing some difficulties. On January 30, the company disclosed a profit forecast, stating that its healthcare informatization business has been affected by macroeconomic conditions, industry demand fluctuations, intensified market competition, and the fact that WiNEX products are still in the process of upgrading and replacement, which has led to a temporary operational challenge. It is expected that the net profit attributable to the parent company for 2025 will be a loss of 320 million to 390 million yuan.

The company stated that in response to these changes, it has implemented multiple cost-saving and expense-control measures. However, factors such as fixed expenses that cannot decrease proportionally with revenue, impairment provisions, goodwill impairments, tax and late payment surcharges, and the optimization (partial shutdown or divestment) of internet healthcare businesses have led to declines in overall revenue and profit during the reporting period.

Cover image source: AIGC